Аналитики Zacks повысили прогноз по прибыли Ironwood Pharmaceuticals до $1,10 на акцию в 2026 году

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) – Analysts at Zacks Research increased their FY2026 earnings per share estimates for shares of Ironwood Pharmaceuticals in a report released on Thursday, August 27th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $1.10 per share for the year, up from their previous estimate of $1.04. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $1.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q1 2028 earnings at $0.02 EPS and Q2 2028 earnings at $0.01 EPS. IRWD has been the subject of several other reports. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd. Weiss Ratings upgraded shares of Ironwood Pharmaceuticals from a “hold (c-)” rating to a “hold (c+)” rating in a research note on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $6.23. Ironwood Pharmaceuticals Stock Performance Shares of NASDAQ:IRWD opened at $4.27 on Monday. The company’s fifty day moving average is $4.16 and its two-hundred day moving average is $3.89. Ironwood Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $5.78. The stock has a market capitalization of $705.57 million, a price-to-earnings ratio of 5.55 and a beta of 0.20. Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.31 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.The business had revenue of $113.04 million during the quarter, compared to analyst estimates of $114.84 million. Insiders Place Their Bets In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the firm’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $4.52, for a total value of $578,062.80. Following the sale, the insider directly owned 313,680 shares in the company, valued at approximately $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julie Mchugh sold 21,571 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director owned 250,749 shares in the company, valued at $935,293.77. The trade was a 7.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 9.30% of the stock is owned by corporate insiders. Institutional Trading of Ironwood Pharmaceuticals Large investors have recently modified their holdings of the company. AQR Capital Management LLC lifted its position in Ironwood Pharmaceuticals by 535.8% in the 1st quarter. AQR Capital Management LLC now owns 2,523,875 shares of the biotechnology company’s stock valued at $3,710,000 after purchasing an additional 2,126,889 shares during the last quarter. Millennium Management LLC grew its position in Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Ironwood Pharmaceuticals in the 1st quarter worth about $57,000. Goldman Sachs Group Inc. grew its position in Ironwood Pharmaceuticals by 72.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,575,416 shares of the biotechnology company’s stock worth $2,316,000 after purchasing an additional 660,144 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Ironwood Pharmaceuticals by 740.5% in the first quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock valued at $5,160,000 after purchasing an additional 3,092,475 shares during the period. Ironwood Pharmaceuticals Company Profile Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S. Featured Articles Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.